<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665573</url>
  </required_header>
  <id_info>
    <org_study_id>120303009906</org_study_id>
    <nct_id>NCT01665573</nct_id>
  </id_info>
  <brief_title>Cannabinoid Augmentation of Fear Response in Humans</brief_title>
  <official_title>Cannabinoid Augmentation of Fear Response in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind, randomized, controlled, proof-of-concept study is to test
      the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On
      three days over not more than two weeks, subjects will be trained to associate cues with two
      different stimuli, then this association will be extinguished. Cannabinoid receptor
      stimulation will be accomplished indirectly by harnessing the brain's capacity to
      endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents
      degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845.
      Some details of this study have not been disclosed to preserve the study design.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    IND placed on clinical hold
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Galvanic skin response</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <description>Measure of sympathetic autonomic activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol levels measured in blood</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <description>Salivary b-amylase and serum cortisol levels will be assessed as neurochemical measures of stress response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fear Conditioning</condition>
  <arm_group>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04457845</intervention_name>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acquisition of conditioning Administration of placebo Extinction of conditioning</description>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 65

          -  Male and female

          -  No major medical problems

        Exclusion Criteria:

          -  Hearing problems

          -  Psychiatric or mental problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohini Ranganathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mohini Ranganathan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Fear Conditioning</keyword>
  <keyword>Cannabinoids</keyword>
  <keyword>Fear Response</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

